On this page

Chlorhexidine Gluconate

ANDA TE AT Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
Chlorhexidine Gluconate
Generic name
Chlorhexidine Gluconate
Dosage form
Liquid
Route
Oral
Marketing category
ANDA · ANDA
Labeler
Xttrium Laboratories, Inc.
Product type
Bulk Ingredient
DEA schedule
Not scheduled
Active ingredients
3
NDC product codes
3
Packages
8
Data completeness
76% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Chlorhexidine Gluconate .12 mg/mL 1667684 View
Chlorhexidine Gluconate 1 g/g 1667684 View
Chlorhexidine Gluconate 1 kg/kg 1667684 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Liquid
Route of administration
Oral
Presentations
11

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Decreased Cell Wall Integrity [PE] PE All 26 members

Regulatory status

Source: Drugs@FDANDC Directory
Application number
077789
Application type
ANDA · Abbreviated New Drug Application
Approval date
June 18, 2009
Sponsor
PHARMOBEDIENT
Products on application
1
Submissions recorded
3
Products approved under application 077789.
Product Trade name Form Strength Ingredient Status TE Flags
077789-001 CHLORHEXIDINE GLUCONATE SOLUTION CHLORHEXIDINE GLUCONATE Prescription AT

Therapeutic equivalence

Source: Orange Book
TE code
AT
Reference Listed Drug
No
Reference Standard
No

What this rating means: Therapeutically equivalent — bioequivalence demonstrated (topical dermatological products)

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 077789.
Type No. Action Status Date Review
Supplement 11 Labeling Approved August 8, 2023 Standard
Supplement 7 Labeling Approved July 28, 2015 Standard
Original application 1 Approved June 18, 2009 —

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20200323). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20200323

Recent Major Changes

openFDA Drug Labeling

Indications and Usage Contraindications

Indications and Usage

openFDA Drug Labeling

INDICATION: Chlorhexidine gluconate oral rinse is indicated for use between dental visits as part of a professional program for the treatment of gingivitis as characterized by redness and swelling of the gingivae, including gingival bleeding upon probing. Chlorhexidine gluconate oral rinse has not been tested among patients with acute necrotizing ulcerative gingivitis (ANUG). For patients having coexisting gingivitis and periodontitis, see PRECAUTIONS.

Dosage and Administration

openFDA Drug Labeling

Chlorhexidine gluconate oral rinse therapy should be initiated directly following a dental prophylaxis. Patietents using chlorhexidine gluconate oral rinse should be reevaluated and given a thorough prophylaxis at intervals no longer than six months. Recommended use is twice daily rinsing for 30 seconds, morning and evening after tooth brushing. Usual dosage is 15 ml (1 tablespoon) of undiluted chlorhexidine gluconate oral rinse. Patients should be instructed to not rinse with water, or other mouthwashes, brush teeth, or eat immediately after using chlorhexidine gluconate oral rinse. Chlorhexidine gluconate oral rinse is not intended for ingestion and shohuld be expectorated after rinsing.

Contraindications

openFDA Drug Labeling

Chlorhexidine gluconate oal rinse should not be used by persons who are known to be hypersensitive to chlorhexidine gluconate or other formula ingredients.

The effect of chlorhexidine gluconate oral rinse on periodontitis has not been determined. An increase in supragingival calculus was noted in clinical testing in chlorhexidine gluconate oral rinse users compared with control users. It is not known if chlorhexidine gluconate oral rinse use results in an increase in subgingival calculus. Calculus deposits should be removed by a dental prophylaxis at intervals not greater than six months. Anaphylaxis, as well as serious allergic reactions, have been reported during postmarketing use with dental products containing chlorhexidine. SEE CONTRAINDICATIONS.

Adverse Reactions

openFDA Drug Labeling

The most common side effects associated with chlorhexidine gluconate oral rinses are: an increase in staining of teeth and other oral surfaces; an increase in calculus formation; and an alteration in taste perception; see WARNINGS and PRECAUTIONS. Oral irritation and local allergy-type symptoms have been spontaneously reported as side effects associated with use of chlorhexidine gluconate rinse. The following oral mucosal side effects were reported during placebo-controlled adult clinical trials: aphthous ulcer, grossly obvious gingivitis, trauma, ulceration, erythema, desquamation, coated tongue, keratinization, geographic tongue, mucocele, and short frenum. Each occured at a frequency of less than 1% Among post marketing reports, the most frequetly reported oral mucosal symptoms assiciated with chlorhexidine gluconate oral rinse are stomatitis, gingivitis, glossitis, ulcer, dry mouth, hypesthesia, glossal edema, and paresthesia. Minor irritation and superfical desquamation of the oral muscosa have been noted in patients using chlorhexidine gluconate oral rinse. There have been cases of parotid gland swelling and inflammation of the salivary glands (sialadenitis) reported in patients using chlorhexidine gluconate oral rinse.

Description

openFDA Drug Labeling

0.12% chlorhexidine gluconate (CHG) is an oral rinse containing (1 1 -hexamethylene bis [5 - (p-chlorophenyl) biguanide] di-D-gluconate) in a base containing wate, 11.6% alcohol, glycerin, PEG-40 sorbitan diisostearate, flavor, sodium saccharin, and FD&C Blue No. 1. Chlorhexidine gluconate product is a near neutral solution (pH range 5-7). Chlorhexidine gluconate is a salt of chlorhexidine and gluconic acid. Its chemical structure is: Chemical structure

Ingestion of 1 or 2 ounces of chlorhexidine gluconate oral rinse by a small child (~10 kg body weight) might result in gatric distress, including nausea, or signs of alcohol intoxication. Medical attention should be sought if more than 4 ounces of chlorhexidine gluconate oral rinse is ingested by a small child or if signs of alcohol intoxication develop.

How Supplied / Storage and Handling

openFDA Drug Labeling

Chlorhexidine gluconate oral rinse is suppplied as a blue liquid in 4-ounce (118 mL) and 1-pint (473 mL) amber plastic bottles with child-resistant dispensing closures. NDC 0116-0101-04 / 0116-0101-01 Store at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F) [See USP controlled Room Temperature] Rx Only Manufactured for: Patterson Dental Supply, Inc. 1031 Mendota Heights Road Saint Paul, MN 55120

Adverse event reports

Source: openFDA FAERS
9,457
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: CHLORHEXIDINE GLUCONATE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
61876-0030-1 61876-0030 DISHMAN CARBOGEN AMCIS LIMITED 1000 kg in 1 DRUM (61876-0030-1) September 8, 2013
38779-2755-1 38779-2755 Medisca Inc 800 g in 1 BOTTLE (38779-2755-1) January 19, 2018
38779-2755-5 38779-2755 Medisca Inc 20 g in 1 BOTTLE (38779-2755-5) August 25, 2015
38779-2755-7 38779-2755 Medisca Inc 4000 g in 1 PAIL (38779-2755-7) January 19, 2018
38779-2755-8 38779-2755 Medisca Inc 100 g in 1 BOTTLE (38779-2755-8) January 19, 2018
38779-2755-9 38779-2755 Medisca Inc 200 g in 1 BOTTLE (38779-2755-9) January 19, 2018
0116-0101-01 0116-0101 Xttrium Laboratories, Inc. 473 mL in 1 BOTTLE (0116-0101-01) June 30, 2017
0116-0101-04 0116-0101 Xttrium Laboratories, Inc. 118 mL in 1 BOTTLE, PLASTIC (0116-0101-04) January 22, 2016
61876-0030 61876-0030 DISHMAN CARBOGEN AMCIS LIMITED — September 8, 2013
38779-2755 38779-2755 Medisca Inc — August 25, 2015
0116-0101 0116-0101 Xttrium Laboratories, Inc. — January 22, 2016

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts

Generated September 25, 2026 · 12 sections on this page.